Daunorubicin

• Powder for solution for infusion vials 20mg

Doxorubicin 

• Solution for injection vials 10mg/5ml, 50mg/25ml
• Solution for infusion vials 20mg/10ml, 100mg/50ml, 200mg/100ml

Pegylated liposomal doxorubicin hydrochloride (PLDH)

• Caelyx pegylated liposomal concentrate for solution for infusion vials 20mg/10ml, 50mg/25ml

Notes

1. NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx), paclitaxel, trabectedin (Yondelis) and gemcitabine for treating recurrent ovarian cancer (April 2016):
   1. PLDH as monotherapy is recommended as an option for treating recurrent ovarian cancer.
   2. PLDH in combination with platinum is recommended as an option for treating recurrent ovarian cancer.
   3. PLDH in combination with trabectedin is not recommended for treating the first recurrence of platinum-sensitive ovarian cancer.
2. MHRA Drug Safety Update (July 2020): Liposomal and lipid-complex formulations: name change to reduce medication errors.

Epirubicin hydrochloride

• Solution for injection vials 10mg/5ml, 50mg/25ml
• Solution for infusion vials 100mg/50ml, 200mg/100ml

Idarubicin hydrochloride

• Capsules 5mg, 10mg
• Powder for solution for injection vials 5mg, 10mg

Mitoxantrone

• Solution for infusion vials 20mg/10ml, 25mg/12.5ml

Pixantrone

• Powder for solution for infusion vials 29mg

Notes

1. NICE TA306: Pixantrone (Pixuvri) monotherapy is recommended as an option for treating adults with multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma (February 2014) only if:
   1. the person has previously been treated with rituximab and
   2. the person is receiving third- or fourth-line treatment and
   3. the manufacturer provides pixantrone with the discount agreed in the patient access scheme.